Medigene (MDG1) - Transition to prominent immunotherapy player

10:20 EDT 3 Aug 2017 | Edison Investment Research

Edison Investment Research - Pharmaceutical & healthcare - Medigene: Medigene’s H1 results are in line with our expectations and represent the completion of its transformation into a prominent T-cell immunotherapy player. Highlights from H1 include submission of a clinical trial authorisation (CTA) to begin its first clinical T-cell trial and a fund-raising of €20.7m (gross). We maintain our valuation at €315m, but expect upside as it executes on its strategy over the next 12-18 months.
ISIN: DE000A1X3W00

Original Article: Medigene (MDG1) - Transition to prominent immunotherapy player


More From BioPortfolio on "Medigene (MDG1) - Transition to prominent immunotherapy player"

Quick Search

Relevant Topic

Health care (or healthcare) is the diagnosis, treatment, and prevention of disease, illness, injury, and other physical and mental impairments in humans. Health care is delivered by practitioners in medicine, chiropractic, dentistry, nursing, pharmacy, a...